Journal: Frontiers in Neural Circuits

Article Title: Central Thalamic Deep-Brain Stimulation Alters Striatal-Thalamic Connectivity in Cognitive Neural Behavior

doi: 10.3389/fncir.2015.00087

Figure Lengend Snippet: Western blot protein analysis of cells excised individually from striatal and hippocampal tissues. (A) The SDS-PAGE blots show the expression of dopamine D2 receptor (Drd2) and α4-nicotinic acetylcholine receptor (α4-nAChR) in the striatum (top) and hippocampus (bottom). (B) Results from the quantitative analysis of Drd2 and α4-nAChR expression (mean ± SEM; expressed as ratio to GAPDH) in the striatum (top) and hippocampus (bottom). Striatal and Drd2 and α4-nAChR protein expressions were significantly increased relative to sham control group. Significant increases in Drd2 and α4-nAChR protein expressions in the hippocampus also were found. * , ** , and *** indicate significant protein expression with P < 0.05, P < 0.01, and P < 0.001, respectively, relative to sham control group.

Article Snippet: The membranes were hybridized with anti-dopamine D2 receptor (Drd2; 1:1000; ADR-002-50UL, Alomone Labs, Jerusalem, Israel) or anti-nicotinic acetylcholine α 4 receptor (α4-nAChR; 1:1000; ANC-004-50UL, Alomone Labs, Jerusalem, Israel) antibodies.

Techniques: Western Blot, SDS Page, Expressing

Journal: Reproductive biomedicine online

Article Title: Social psychogenic stress promotes the development of endometriosis in mouse.

doi: 10.1016/j.rbmo.2016.11.012

Figure Lengend Snippet: Figure 4 – Immmunoreactivity staining of different markers in ectopic lesions in different groups. (A) Representative immunostaining of ADRB2 in endometrium in CONTROL and SHAM mice and in ectopic endometrium in STRESSED and UNSTRESSED mice. ADRB2 and DRD2 immunoreactivity was both seen primarily in glandular epithelial cells and was localized in the cytoplasm. Scale bar = 125 μm. (B) Representative immunostaining of DRD2, VEGF, CD31, CD41, F4/80, PCNA and α-SMA in the ectopic lesions in UNSTRESSED and STRESSED groups. VEGF immunoreactivity was seen primarily in glandular epithelial cells and was localized in the cytoplasm. CD31 immunostainings were seen mostly in vascular endothelial cells. CD41 shows the extent of platelet aggregation and F4/80 immunoreactivity represents the extent of macrophage infiltration. PCNA immunoreactivity was seen both in glandular epithelial cells and stromal cells were localized in the cell nucleus, but the change of immunoreactivity in glandular epithelial cells was more obvious. α-SMA staining were seen mostly in the stromal component of the ectopic lesions. Scale bar = 125 μm. Mice in stressed (STRS) and unstressed (UNSTRS) groups had undergone endometriosis-inducing surgery, while mice the SHAM group underwent non-endometriosis-inducing surgery. Mice in unstressed (UNSTRS), SHAM and control (CTL) groups were not exposed to stress.

Article Snippet: For negative controls, the immunoglobulin G (IgG) from the rabbit serum (Sigma, Darmstadt, Germany) was used instead of primary antibodies against ADRB2, DRD2, VEGF, CD31, CD41, α-SMA and PCNA except for F4/80, for which the IgG was from the rat serum (Boster, Wuhan, China) was used, all used at the same concentration with its corresponding primary antibody.

Techniques: Staining, Immunostaining, Control

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 1. DMCs identified in the DRD2 promoter region of breast cancer tissues (C1-C7) to the paired adjacent tissues (N1-N7). (A) A heatmap of the 8 DMCs in the breast cancer tissues. (B) The mean methylation level, differences, and significance level of these DMCs. (C) The methylation level of these DMCs in cancer tissues and their paired adjacent tissues (negative control).

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Methylation, Negative Control

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 3. Construction of DRD2 overexpression and downregulation models. (A) Representative immunoblot of DRD2 expression of the original MCF-7 cells (Con), MCF-7 with blank vector (NC), and MCF-7 with DRD2 overexpression (OE). (B) The quantification of DRD2 in MCF-7 cells by western blot. (C) Representative immunoblot of DRD2 expression of the original MB231 cells (Con), MB231 with non-target siRNA (shNC), and MB231 with three different shRNAs (shRNA1, shRNA2, shRNA3). (D) The quantification of DRD2 in MB231 cells by western blot. * vs Hs 578Bst/con, P<0.05; # vs NC/shNC, P < 0.05.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Over Expression, Western Blot, Expressing, Plasmid Preparation

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 2. The expression levels of DRD2 in breast cancer cells. (A) Representative immunoblot of DRD2 expression of the breast cancer cells (MCF-7, SK-BR3, and MB231) and normal breast cells (Hs 578Bst). (B-C) The relationship between DRD2 and β-actin was detected by PCR, and the relationship between DRD2 and α-tublin was detected by western blot. * vs Hs 578Bst, P<0.05.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Expressing, Western Blot

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 4. DRD2 promotes the proliferation and migration of breast cancer cells. (A) Proliferation of MB231 treated with different concentrations of 5-AzadC. (B) Proliferation of original MCF-7 cells (Con), MCF-7 with blank vector (NC), and MCF-7 with DRD2 overexpression (OE). (C) Proliferation of original MB231 cells (Con), MB231 with non-target siRNA (shNC), MB231 with DRD2 shRNA (shRNA), and MB231 with DRD2 shRNA plus 5-AzadC (shRNA + 5-AzadC). (D) Statistics for migration of Con, NC, and OE cells. (E) Representative cell images for the migration ability of Con, NC, and OE cells. (F) Statistics for migration of Con, shNC, shRNA, and shRNA + 5-AzadC cells. (G) Representative cell images for the migration ability of Con, shNC, shRNA, and shRNA + 5-AzadC cells. * vs con, P < 0.05; # vs NC/ shNC, P < 0.05; $ vs shRNA, P < 0.05.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Migration, Plasmid Preparation, Over Expression, shRNA

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 5. DRD2 promotes cancer through ERK signaling pathway. (A) Western blot for DRD2, ERK and p-ERK expression in primary MCF-7 cells (Con), blank vector (NC) and DRD2 overexpressing (OE). (B-E) Quantitative analysis of FLNA, ERK, p-ERK and DRD2 expression in different MCF-7 cells. (F) Western blot of DRD2 expression in primary MB231 cells (Con), MB231 and non-target siRNA (shNC), MB231 and DRD2 shRNA (shRNA), MB231 and DRD2 shRNA + 5-AzadC (shRNA + 5- AzadC) . (G-J) Quantitative analysis of FLNA, ERK, p-ERK and DRD2 expression in different MB231 cells.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Western Blot, Expressing, Plasmid Preparation, shRNA

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 6. The expression of DRD2 regulated tumor growth in vivo. (A, D) Subcutaneous xenograft model images of blank vector (NC) and DRD2-overexpressing MCF-7 cells (OE) in nude mice and their tumors. (B) Tumor growth curves of NC group and OE group. (C) Tumor weights in NC group and OE group. (E) Expression of Ki67 and CD31 in NC and OE tissues.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Expressing, In Vivo, Plasmid Preparation

Journal: Cancer genetics

Article Title: Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway.

doi: 10.1016/j.cancergen.2023.09.001

Figure Lengend Snippet: Fig. 7. Detection of protein levels in subcutaneous tumor tissue. (A) Western blot analysis of FLNA, DRD2, ERK and p-ERK expression in MCF-7-NC and MCF-7-OE tissues. (B) Quantitative analysis of FLNA, ERK, p-ERK and DRD2 expression in MCF-7-NC and MCF-7-OE tissues. (C) Representative immunoblots of FLNA, DRD2, ERK and p-ERK expression in MB231-shNC, MB231-shRNA and MB231-shRNA+5-AzadC tissues. (D) Quantitative analysis of FLNA, ERK, p-ERK, DRD2 expression in MB231-shNC, MB231-shRNA, MB231-shRNA+5-AzadC tissues.

Article Snippet: Antibodies against DRD2 (SC-5303, Santa, USA), ERK (4695S, CST, USA), p-ERK (4370S, CST, USA), and α-tublin (66,031–1-ig, proteintech, USA) were used for Western blot analysis.

Techniques: Western Blot, Expressing, shRNA